WS
NTLA icon

Wedbush Securities’s Intellia Therapeutics NTLA Stock Holding History

Wedbush Securities’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,258
Closed -$237K – 1143
2022
Q1 		$237K Sell
3,258
-196
-6% -$16.6K 0.01% 909
2021
Q4 		$408K Buy
3,454
+7
+0.2% +$877 0.02% 722
2021
Q3 		$462K Sell
3,447
-394
-10% -$59.7K 0.02% 649
2021
Q2 		$622K Sell
3,841
-5,146
-57% -$401K 0.03% 536
2021
Q1 		$721K Buy
+8,987
New +$603K 0.04% 434

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wedbush Securities's NTLA Position: Q2 2022 in Review

Wedbush Securities sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 3,258 shares — an estimated $237K sold.

Wedbush Securities first reported a position in NTLA in Q1 2021 and held it in 5 quarters. The position peaked at $721K in Q1 2021. 299 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

  • Wedbush Securities reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Wedbush Securities sold 3,258 Intellia Therapeutics shares in Q2 2022, an estimated $237K.
  • Wedbush Securities first reported a position in Intellia Therapeutics in Q1 2021 and held it in 5 quarters.
  • Wedbush Securities's Intellia Therapeutics position peaked at $721K in Q1 2021.
  • 299 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on Wedbush Securities's 13F filing for Q2 2022, filed 21 Jul 2022.